RMC No. 110-2022 updates VAT-exempt medicines under CREATE, covering certain cancer and COVID-19 medicines effective upon FDA publication.

Businesses selling, purchasing, importing, prescribing, or accounting for medicines used in cancer and COVID-19 treatment must verify whether the specific medicines they handle are now included in the updated List of VAT-Exempt Medicines. RMC No. 110-2022 matters because VAT treatment for covered medicines under Republic Act No. 11534, or the CREATE Act, depends on inclusion in the Food and Drug Administration-endorsed list and takes effect from the date the FDA publishes the update.

What RMC No. 110-2022 Changed

RMC No. 110-2022, issued on July 21, 2022, publishes the May 30, 2022 letter from Food and Drug Administration OIC-Director General Oscar G. Gutierrez, Jr. endorsing updates to the List of VAT-Exempt Medicines under the CREATE Act. The update adds certain medicines prescribed for cancer and COVID-19 treatment to the list of medicines that may qualify for VAT exemption.

The key tax consequence is practical and immediate: once the FDA publishes the updated list, the VAT exemption for the covered medicines and medical devices takes effect. This is consistent with the clarification in Q&A No. 1 of RMC No. 99-2021, which states that the effectivity of the VAT exemption of covered medicines and medical devices under the CREATE Act is reckoned from the FDA publication date of the updates to the list.

For businesses, the change is not merely an internal tax classification issue. It affects invoicing, pricing, VAT reporting, input tax review, product master data, inventory coding, accounting treatment, and customer communications. Pharmacies, hospitals, clinics, distributors, importers, manufacturers, and corporate purchasers of covered medicines should not assume that all cancer medicines or all COVID-19 medicines are VAT-exempt. The exemption applies to covered medicines included in the updated List of VAT-Exempt Medicines.

Who Is Most Affected by RMC No. 110-2022

The most affected taxpayers are VAT-registered sellers and distributors of medicines, especially those carrying cancer treatment medicines and COVID-19 treatment medicines. Pharmacies, drugstores, hospital pharmacies, healthcare institutions, medicine wholesalers, importers, and pharmaceutical companies should review their product lists against the FDA-published updates.

Corporate accountants and tax managers of hospitals and healthcare groups should also take note because incorrect VAT treatment may affect sales invoices, official receipts, tax returns, revenue recognition, and audit exposure. A seller that continues to impose VAT on a medicine that is already covered by the updated VAT-exempt list may face customer disputes and accounting reversals. Conversely, a seller that treats a medicine as VAT-exempt without confirming its inclusion in the updated list risks under-declaring VAT on taxable sales.

Business owners and CFOs searching for VAT exemption on medicines Philippines, CREATE Act VAT-exempt medicines, cancer medicines VAT exemption, COVID-19 medicines VAT exemption, and FDA List of VAT-Exempt Medicines should treat RMC No. 110-2022 as a compliance trigger. It signals that the tax treatment of specific medicines may have changed and that accounting systems should be updated based on the FDA-published list.

Key Compliance Requirement: Verify the FDA-Published List Before Applying VAT Exemption

The central compliance requirement under RMC No. 110-2022 is verification. The circular does not create a blanket VAT exemption for every product related to cancer or COVID-19. It publishes the FDA endorsement of updates to the List of VAT-Exempt Medicines and confirms the applicable rule on effectivity. Therefore, taxpayers must identify whether the specific medicine is included in the updated list published by the FDA.

This distinction is important for VAT-registered businesses. A product description such as cancer medicine, chemotherapy medicine, antiviral medicine, or COVID-19 treatment medicine is not by itself enough to support VAT exemption. The safer compliance approach is to match the product against the FDA-published List of VAT-Exempt Medicines, retain documentation of the applicable list, and apply the VAT exemption only from the relevant FDA publication date.

Businesses should also ensure that their point-of-sale systems, enterprise resource planning systems, invoice templates, product tax codes, and accounting ledgers are updated. Tax teams should coordinate with pharmacy operations, procurement, sales, and finance to avoid inconsistent VAT treatment across branches, warehouses, online ordering systems, and manual billing channels.

Effective Date and Deadline Considerations

RMC No. 110-2022 was issued on July 21, 2022. However, the operational effectivity rule stated in the circular is more specific: as clarified under Q&A No. 1 of RMC No. 99-2021, the VAT exemption of covered medicines and medical devices under the CREATE Act takes effect on the date the FDA publishes the updates to the List of VAT-Exempt Medicines.

This means taxpayers should not rely solely on the July 21, 2022 issuance date when determining when to stop charging VAT on a covered medicine. The relevant date for applying the VAT exemption is the FDA publication date of the update covering the medicine. For audit readiness, taxpayers should retain a copy or record of the FDA-published update showing that the medicine was included and indicating when the update became published.

No separate filing deadline, registration deadline, or application procedure is stated in RMC No. 110-2022. The immediate business action is internal compliance: review the updated list, correct product tax coding, and preserve documentation supporting the VAT-exempt treatment.

Penalties and Audit Risks for Non-Compliance

RMC No. 110-2022 does not state a special penalty provision. However, incorrect VAT treatment may still create ordinary tax compliance exposure under existing tax rules. A business that fails to charge VAT on a medicine not covered by the FDA-published list may face assessment risk for deficiency VAT, surcharge, interest, and compromise penalties under applicable tax laws and regulations.

On the other hand, charging VAT on a medicine that should already be treated as VAT-exempt may create commercial and accounting issues, particularly for hospitals, pharmacies, and healthcare suppliers dealing with patients, institutional buyers, and government or private healthcare programs. The risk is not only tax-related. It may affect pricing, customer trust, reimbursement computations, and reconciliation of sales records.

For CFOs and corporate accountants, the most practical risk is inconsistency. If one branch treats a medicine as VAT-exempt while another branch charges VAT, the company may face reconciliation issues during VAT return preparation and BIR audit. A documented, centralized tax coding process is therefore essential.

Practical Steps for Businesses

First, identify all medicines in inventory or product catalogs that are prescribed for cancer and COVID-19 treatment. Second, compare those products against the FDA-published updated List of VAT-Exempt Medicines endorsed in connection with RMC No. 110-2022. Third, determine the FDA publication date applicable to the update, because that date controls when the VAT exemption takes effect.

Fourth, revise the VAT classification of covered medicines in accounting, invoicing, and point-of-sale systems. Fifth, instruct finance, sales, billing, pharmacy, procurement, and compliance teams that the exemption applies only to medicines covered by the updated list, not to all medicines associated with cancer or COVID-19. Sixth, retain supporting documentation for audit purposes, including the relevant FDA-published list and internal tax coding approvals.

Finally, review prior transactions from the effective FDA publication date onward to determine whether any VAT treatment correction is necessary. This review is especially important for high-volume pharmacies, hospitals, and distributors where even small coding errors can result in significant aggregate VAT exposure.

How Ablola, Saribong & Gueco Can Help

RMC No. 110-2022 is a reminder that VAT exemption on medicines is a documentation-driven compliance issue. Businesses cannot rely on general product categories alone. They must confirm inclusion in the FDA-published List of VAT-Exempt Medicines, determine the correct effectivity date, and align invoicing and accounting systems with the BIR-recognized treatment.

Ablola, Saribong & Gueco assists pharmacies, hospitals, healthcare suppliers, pharmaceutical distributors, importers, and corporate taxpayers in reviewing VAT classification, preparing BIR audit documentation, correcting invoicing practices, and designing practical tax compliance procedures. For assistance with RMC No. 110-2022, CREATE Act VAT exemptions, and BIR compliance for medicines and healthcare products, contact Ablola, Saribong & Gueco through MakatiLawFirm.com.


Leave a Comment

Your email address will not be published. Required fields are marked *